The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a small study.

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting algorithm.

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more here.

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors | Presented at the annual meeting of the European Society for Medical Oncology,